Ulcerative Colitis Clinical Trial
— ATICCAOfficial title:
An Open Randomized Multicenter Clinical Investigation to Compare the Efficacy and Safety of Prednisone Plus Adacolumn® GMA Apheresis vs Prednisone Alone in the Treatment of Patients With Mild or Moderately Active Steroid Dependent Ulcerative Colitis
The purpose of this study is to evaluate the efficacy of the addition of GMA apheresis to steroid conventional treatment for achieving and maintaining remission in Active steroid dependant Ulcerative Colitis patients
Status | Terminated |
Enrollment | 133 |
Est. completion date | July 2013 |
Est. primary completion date | July 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - 18 - 75 years old - Active ulcerative colitis with documented clinical symptoms and endoscopic findings - Active disease defined as DAI (Mayo score) = 4 and =10 with at least 1 point in flexible sigmoidoscopy - Steroid dependency as defined by: A. Inability to withdraw corticosteroids within three months of starting treatment, without recurrent active disease B. appearance of relapse within 3 months after withdrawal of corticosteroids - Colonic involvement with ulcerative colitis beyond 15cm of the anal verge - Stable doses:A. Aminosalicylates for the last 4 weeks B. Prednisolone or equivalent dose = 20 mg/day for the last 2 weeks C. Azathioprine or 6-mercaptopurine at stable dose for the last 12 weeks - Signed informed consent form - Agree to participate in the required follow-up visits - Able to complete the diary Exclusion Criteria: - Febrile (> 38ºC) - Evidence of toxic megacolon - Anticipated need for surgery within 24 weeks - Known obstructive diseases of the gastrointestinal system - Proctocolectomy, total colectomy, ileostomy, stoma or ileal pouch-anal anastomosis - A history of allergic reaction to heparin or heparin-induced thrombocytopenia - A history of hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures - Requires a central venous access catheter for the apheresis treatments - Known infection with enteric pathogens, pathogenic ova or parasites, C. difficile toxin or CMV - Hypotension (systolic blood pressure <80 mmHg and/or diastolic blood pressure <50 mmHg) at screening visit only - Uncontrolled hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure >120 mmHg) despite medical therapy - A history of myocardial infarction or unstable angina within the past 6 months - A history of coronary artery bypass grafting surgery or angioplasty within the past 6 months - Prosthetic heart valve, pacemaker or other permanent implant - Severe cardiovascular or peripheral vascular disease, severe renal disease - Liver disease defined as levels of SGOT [AST], SGPT [ALT] or alkaline phosphatase >2.5x the upper limit of the normal range for the laboratory performing test - History of cirrhosis - Known bleeding disorder (PT or PTT>1.5x the upper limit of the normal range for the laboratory performing the test), or concomitant anticoagulant therapy for purposes other than apheresis treatment - Prior history suggestive of a hypercoagulable disorder, including 1 or more episodes of pulmonary embolism or deep vein thrombosis - Known infection with Hepatitis B or C, or HIV - Abnormal hematology parameters defined as severe anemia with hemoglobin <8.5g/dL, white blood cell count of <3,500/µl and a granulocyte count < 2,000/µl - Fibrinogen level >700mg/dL - Major surgery within the past 6 months - Infection:Active infections less than 4 weeks from successful completion of antibiotic treatment for routine bacterial infectionFebrile viral infection within 4 weeks of entry into the clinical investigationLess than 12 weeks from conclusion of therapy for systemic fungal infections - Malignancy within the past 2 years other than surgically cured skin carcinoma or cervical dysplasia (CIN I-II) - History of dysplasia or carcinoma of the colon or lack of a complete colonoscopy in the last 12 months in patients with longstanding UC (> 10 años) - Current drug or alcohol abuse - Pregnant, lactating or planning to become pregnant during the course of the clinical investigation - Used within the last 30 days an investigational drug, biologic or device or 5 half-lifes, if known, for any investigational drug or biologic - Received cyclosporine or tacrolimus within the last 8 weeks - Received infliximab within the last 8 weeks - Fulminant ulcerative colitis |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Austria | Medical University of Vienna | Vienna | |
Germany | Katolische Kliniken Ruhrhalbinsel | Essen | |
Germany | Markus-Krankenhaus | Frankfurt | |
Italy | Policlinico di Bari | Bari | |
Italy | Ospedale di Belluno | Belluno | |
Italy | Azienda Ospedaliero-Universitaria di Careggi | Firenze | |
Italy | L'Azienda Unità Sanitaria Locale di Forlì | Forli | |
Italy | Istituto Policlinico S. Donato | Milan | |
Italy | Policlinico di Padova | Padova | |
Italy | Policlinico Universitario Tor Vergata | Roma | |
Italy | Istituto Clinico Humanitas | Rozzano | |
Italy | Casa Sollievo della Sofferenza, Istituto di Ricovero e Cura a Carattere Scientifico, Opera di San Pio da Pietrelcina | San Giovanni Rotondo | |
Portugal | Hospital da Universidade de Coimbra | Coimbra | |
Portugal | Hospital Santa Maria | Lisboa | |
Portugal | Instituto Portuges Oncologia Lisboa Francisco Gentil | Lisboa | |
Portugal | Hospital de Sao Joao | Porto | |
Portugal | Hospital Geral Santo Antonio | Porto | |
Portugal | Hospital de Sao Bernardo | Setubal | |
Portugal | Hospital Sao Teotonio | Viseu | |
Spain | Complejo Hospitalario Universitario Juan Canalejo | A Coruña | Galicia |
Spain | Complejo Universitario de Albacete | Albacete | |
Spain | Hospital General Universitario de Alicante | Alicante | |
Spain | Hospital Germans Trias i Pujol | Badalona | Barcelona |
Spain | Hospital Clinic i Provincial | Barcelona | |
Spain | Hospital de la Santa Creu i Sant Pau | Barcelona | |
Spain | Hospital del Mar | Barcelona | |
Spain | Complejo Hospitalario Reina Sofía | Córdoba | Andalucía |
Spain | Hospital General de Elche | Elche | Alicante |
Spain | Hospital de Galdakano | Galdakao | Bilbao |
Spain | Hospital Josep Trueta | Girona | |
Spain | Hospital Universitario de Bellvitge | Hospitalet de Llobregat | Barcelona |
Spain | Hospital Insular de Las Palmas | Las Palmas de Gran Canaria | |
Spain | Hospital de Leon | Leon | |
Spain | Clínica Puerta de Hierro | Madrid | |
Spain | Hospital Fundación de Alcorcón | Madrid | |
Spain | Hospital Universitario Clínico de San Carlos | Madrid | |
Spain | Hospital Costa del Sol | Málaga | |
Spain | Hospital Virgen de la Arrixaca | Murcia | |
Spain | Hospital Central de Asturias | Oviedo | Asturias |
Spain | Hospital Son Dureta | Palma de Mallorca | Comunidad Balear |
Spain | Hospital de Navarra | Pamplona | Navarra |
Spain | Hospital Puerto de Sagunto | Sagunto | Valencia |
Spain | Hospital de Donostia | San Sebastian | Guipuzcoa |
Spain | Complejo Hspitalario Universitario Santiago de Compostela | Santiago de Compostela | A Coruña |
Spain | Hospital Universitario Virgen del Rocío | Sevilla | |
Spain | Hospital Mutua de Terrassa | Terrassa | Barcelona |
Spain | Hospital de Manises | Valencia | |
Spain | Hospital do Meixoeiro | Vigo |
Lead Sponsor | Collaborator |
---|---|
Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa |
Austria, Germany, Italy, Portugal, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of patients in steroid free clinical remission defined by Mayo Score less or equal to 2 with no individual subscore >1 at week 24 | week 24 | No | |
Secondary | Steroid free remission (assessed by Mayo score) | Week 12 | No | |
Secondary | Response at week 12 and 24 (defined by a decrease in Mayo Score > or = to 3 points | week 12 and week 24 | No | |
Secondary | Acute Phase reactants change at all lab analysis | 24 weeks | No | |
Secondary | Rescue therapy requirements (new courses of steroids, cyclosporine, infliximab, or surgery) during study period | 24 weeks | No | |
Secondary | Time to relapse | 24 weeks | No | |
Secondary | · Clinical response according to the activity indexes Truelove & Witts, Powell Tuc, Rachmiliewitz (Clinical Activity Index), Lichtiger (Modified Truelove & Witts Severity Index), Walmsley (Simple Clinical Colitis Index | 24 weeks | No | |
Secondary | Clinical remission and response at weeks 12 and 24 analysed according to concomitant use of immunosupressants | 24 weeks | No | |
Secondary | Adverse events | 24 weeks | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05702879 -
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
|
||
Not yet recruiting |
NCT05953402 -
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Recruiting |
NCT03950232 -
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03124121 -
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
|
Phase 4 | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Withdrawn |
NCT04209556 -
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
|
Phase 2 | |
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT04398550 -
SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis
|
N/A | |
Recruiting |
NCT04314375 -
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
|
Phase 4 | |
Active, not recruiting |
NCT04857112 -
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Active, not recruiting |
NCT04033445 -
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Active, not recruiting |
NCT06221995 -
Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
Completed |
NCT03760003 -
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
|
Phase 2 | |
Not yet recruiting |
NCT05539625 -
Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis
|
Phase 2 |